Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
Pipeline Advancing with Additional Programs Moving into Clinical Development
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2013.
Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results
WATERTOWN, Mass.--(BUSINESS WIRE)--March 06, 2014-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter and full year ended December 31, 2013.
Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results
- Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 -
- Phase 3 trial of RPC1063 in relapsing multiple sclerosis has begun enrolling patients -
- Top-line data from Phase 2 trial of RPC1063 in ulcerative colitis expected in mid-2014 -
Moderna Appoints Biotechnology Investment Banking Veteran Lorence Kim as Chief Financial Officer
CAMBRIDGE, Mass., March 6, 2014 /PRNewswire/ -- Moderna Therapeutics, the p
Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005
BIND Therapeutics Promotes Key Executives: Organization Positioned for Continued Growth
Appoints Andrew Hirsch as Chief Operating Officer and Jeff Hrkach as Chief Technology Officer
Eleven Biotherapeutics Appoints Paul Chaney to Its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Paul Chaney, President and Chief Executive Officer of PanOptica, Inc., to the Company's board of directors.
Joule Appoints David Anton Chief Technology Officer
Bedford, MA – February 28, 2014 –Joule today announced the appointment of David Anton as Executive Vice President and Chief Technology Officer. In this newly-created role, Dr. Anton will lead the transition of Joule’s CO2-to-fuels technology into a commercial reality. He brings nearly 30 years of relevant experience to the company, including prior technology and business leadership roles at DuPont and Codexis.
Joule Names Paul Snaith as New President and CEO
Bedford, MA – February 20, 2014 – Joule today announced the appointment of Paul Snaith as President and Chief Executive Officer, following his most recent post as Chief Operating Officer. He assumes the role from Noubar Afeyan, Executive Chairman and Founder of Joule, who had been serving as interim CEO.
Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease
Patient Randomization and Dosing Underway